Prasugrel Hydrochloride
FDA-approved product (tablet, oral), marketed as Effient, Prasugrel, Prasugrel Hydrochloride.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Acute coronary syndrome
- Hemorrhage
- Intermediate coronary syndrome
- Myocardial infarction
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Platelet aggregation inhibitors excl. heparin
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA64.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli54.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae44.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis64.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Prasugrel Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Nafarelin AcetateExisting use: Endometriosis58.6% AI-predicted activityagainst E. coli12 registered studies
- Goserelin AcetateExisting use: Breast cancer, Breast carcinoma, Carcinoma and 1 more58.5% AI-predicted activityagainst E. coli50+ registered studies
- Doxazosin MesylateExisting use: Benign prostatic hyperplasia, Hypertension, Myocardial infarction58.3% AI-predicted activityagainst E. coli50+ registered studies
- Chlorhexidine GluconateExisting use: Eye infection, Gingivitis, Infection and 2 more58.1% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- Zavegepant HydrochlorideExisting use: Migraine disorder57.8% AI-predicted activityagainst E. coliNo documented evidence found
- Bremelanotide AcetateExisting use: Mental or behavioural disorder, Physiological sexual disorder, Sexual dysfunction57.4% AI-predicted activityagainst E. coli1 registered study
- Trametinib Dimethyl SulfoxideExisting use: Cancer, Cutaneous melanoma, Glioblastoma multiforme and 5 more57.2% AI-predicted activityagainst E. coli16 registered studies
- Degarelix AcetateExisting use: Prostate adenocarcinoma, Prostate cancer, Prostate carcinoma57.2% AI-predicted activityagainst E. coli50+ registered studies
- Cisapride MonohydrateExisting use: Gastrointestinal disease56.3% AI-predicted activityagainst E. coli5 registered studies
- Prazosin HydrochlorideExisting use: Diabetes mellitus, Hypertension56.3% AI-predicted activityagainst E. coli50+ registered studies
- PemigatinibExisting use: Cancer, Cholangiocarcinoma, Neoplasm56.0% AI-predicted activityagainst E. coli50+ registered studies
- AtogepantExisting use: Migraine disorder56.0% AI-predicted activityagainst E. coli36 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Tailored Antiplatelet Therapy Versus Recommended Dose of Prasugrel
NCT01538446 · start 2012-03
Registered record
- Registry ID
- NCT01538446
- Conditions
- Acute Coronary Syndrome
- Interventions
- Modification of Prasugrel based on a biological assay; prasugrel / clopidogrel; Verify Now
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2012-03
- Completion
- 2016-05
- Enrolment
- 880
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Coronary SyndromeInterventionModification of Prasugrel based on a biological assay; prasugrel / clopidogrel; Verify NowPhasePhase 4Registry statusCompletedPharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease
NCT01587651 · start 2012-03
Registered record
- Registry ID
- NCT01587651
- Conditions
- Coronary Artery Disease
- Interventions
- Prasugrel Loading Dose; Prasugrel Maintenance Dose; Ticagrelor Maintenance Dose
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2012-03
- Completion
- 2013-02
- Enrolment
- 110
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCoronary Artery DiseaseInterventionPrasugrel Loading Dose; Prasugrel Maintenance Dose; Ticagrelor Maintenance DosePhasePhase 4Registry statusCompletedRandomized, Open Label Trial of 6 Months Versus 12 Months DAPT After Drug-Eluting Stent in STEMI
NCT01459627 · start 2011-12
Registered record
- Registry ID
- NCT01459627
- Conditions
- Myocardial Infarction; Cardiovascular Disease
- Interventions
- 6 months DAPT; 12 months DAPT
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2011-12
- Completion
- 2017-08
- Enrolment
- 1,100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMyocardial Infarction; Cardiovascular DiseaseIntervention6 months DAPT; 12 months DAPTPhasePhase 4Registry statusCompletedPrasugrel With Lower Dose - Loading Dose
NCT02070159 · start 2011-12
Registered record
- Registry ID
- NCT02070159
- Conditions
- Coronary Artery Disease
- Interventions
- Clopidogrel 600 mg; Prasugrel 30 mg; Prasugrel 60 mg
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2011-12
- Completion
- 2013-01
- Enrolment
- 43
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCoronary Artery DiseaseInterventionClopidogrel 600 mg; Prasugrel 30 mg; Prasugrel 60 mgPhasePhase 3Registry statusCompletedPrasugrel Versus Clopidogrel to TREAT High Platelet Reactivity
NCT01493999 · start 2011-09
Registered record
- Registry ID
- NCT01493999
- Conditions
- Acute Coronary Syndrome
- Interventions
- Clopidogrel reloading; Prasugrel
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2011-09
- Completion
- 2013-04
- Enrolment
- 147
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Coronary SyndromeInterventionClopidogrel reloading; PrasugrelPhasePhase 4Registry statusCompletedEarly Thienopyridine Treatment to Improve Primary PCI in Patients With Acute MI
NCT01327534 · start 2011-05
Registered record
- Registry ID
- NCT01327534
- Conditions
- Myocardial Infarction; STEMI
- Interventions
- Prasugrel; Clopidogrel
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2011-05
- Completion
- 2013-07
- Enrolment
- 63
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMyocardial Infarction; STEMIInterventionPrasugrel; ClopidogrelPhasePhase 3Registry statusCompletedTicagrelor Versus Prasugrel in Acute Coronary Syndromes After Percutaneous Coronary Intervention
NCT01360437 · start 2011-05
Registered record
- Registry ID
- NCT01360437
- Conditions
- Coronary Artery Disease; Acute Coronary Syndrome
- Interventions
- Prasugrel; Ticagrelor
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2011-05
- Completion
- 2011-12
- Enrolment
- 44
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCoronary Artery Disease; Acute Coronary SyndromeInterventionPrasugrel; TicagrelorPhasePhase 3Registry statusCompletedPrasugrel in Comparison to Clopidogrel for Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI)
NCT01338909 · start 2011-04
Registered record
- Registry ID
- NCT01338909
- Conditions
- Myocardial Infarction
- Interventions
- Prasugrel; Clopidogrel
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2011-04
- Completion
- 2011-09
- Enrolment
- 35
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMyocardial InfarctionInterventionPrasugrel; ClopidogrelPhasePhase 3Registry statusCompletedPrasugrel Versus Double Dose Clopidogrel to Treat Clopidogrel Low-responsiveness After PCI
NCT01135667 · start 2010-09
Registered record
- Registry ID
- NCT01135667
- Conditions
- Coronary Artery Disease; Percutaneous Coronary Intervention; Acute Coronary Syndromes
- Interventions
- clopidogrel; Prasugrel 10 mg
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2010-09
- Completion
- 2012-08
- Enrolment
- 106
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCoronary Artery Disease; Percutaneous Coronary Intervention; Acute Coronary SyndromesInterventionclopidogrel; Prasugrel 10 mgPhasePhase 4Registry statusCompletedDouble the Dose of Clopidogrel or Switch to Prasugrel to Antagonize Proton Pump Inhibitor Interaction.
NCT01175200 · start 2010-09
Registered record
- Registry ID
- NCT01175200
- Conditions
- Anti Platelet Effects
- Interventions
- Clopidogrel; Prasugrel; Lansoprazole; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2010-09
- Completion
- 2012-07
- Enrolment
- 82
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAnti Platelet EffectsInterventionClopidogrel; Prasugrel; Lansoprazole; PlaceboPhaseNot applicableRegistry statusCompletedFIT (Fast Infarction Treatment): Complete Revascularization During Primary Percutaneous Coronary Intervention (PCI) Can be Achieved Safely With an Improved Clinical Outcome During the Indexed Hospitalization.
NCT01160900 · start 2010-07
Registered record
- Registry ID
- NCT01160900
- Conditions
- Myocardial Infarction; Ischemia; Heart Failure; Necrosis; Stents
- Interventions
- Coronary angioplasty all lesions
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Unknown
- Start
- 2010-07
- Completion
- 2012-07
- Enrolment
- 180
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMyocardial Infarction; Ischemia; Heart Failure; Necrosis +1 moreInterventionCoronary angioplasty all lesionsPhasePhase 3Registry statusUnknownPrasugrel Versus Placebo in Adult Sickle Cell Disease
NCT01167023 · start 2010-07
Registered record
- Registry ID
- NCT01167023
- Conditions
- Sickle Cell Anemia
- Interventions
- Prasugrel; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2010-07
- Completion
- 2011-06
- Enrolment
- 62
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSickle Cell AnemiaInterventionPrasugrel; PlaceboPhasePhase 2Registry statusCompletedAn Assessment of Prasugrel on Healthy Adults and Sickle Cell Adults
NCT01178099 · start 2010-07
Registered record
- Registry ID
- NCT01178099
- Conditions
- Anemia, Sickle Cell
- Interventions
- Prasugrel
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2010-07
- Completion
- 2011-01
- Enrolment
- 26
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAnemia, Sickle CellInterventionPrasugrelPhasePhase 1Registry statusCompletedPlavix, Prasugrel and Drug Eluting Stents Pilot Trial
NCT01103843 · start 2010-04
Registered record
- Registry ID
- NCT01103843
- Conditions
- Coronary Artery Disease; Platelet Aggregation Inhibitors; PCI- Percutaneous Coronary Intervention
- Interventions
- Loading Dose Arm; Maintenance Dose Arm
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2010-04
- Completion
- 2011-05
- Enrolment
- 1,000
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCoronary Artery Disease; Platelet Aggregation Inhibitors; PCI- Percutaneous Coronary InterventionInterventionLoading Dose Arm; Maintenance Dose ArmPhaseNot applicableRegistry statusUnknownComparison of Prasugrel and Clopidogrel in Very Elderly and Non-Elderly Patients With Stable Coronary Artery Disease
NCT01107912 · start 2010-03
Registered record
- Registry ID
- NCT01107912
- Conditions
- Coronary Artery Disease
- Interventions
- prasugrel; clopidogrel
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2010-03
- Completion
- 2011-10
- Enrolment
- 155
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCoronary Artery DiseaseInterventionprasugrel; clopidogrelPhasePhase 1Registry statusCompleted